Terms: = Lymphoma AND SDC4, ENSG00000124145, 6385, P31431, SYND4, MGC22217
6 results:
1. Concurrent classic driver oncogenes mutation with ROS1 rearrangement predicts superior clinical outcome in NSCLC patients.
Li D; Jiang H; Jin F; Pan L; Xie Y; Zhang L; Li C
Genes Genomics; 2023 Jan; 45(1):93-102. PubMed ID: 36445572
[TBL] [Abstract] [Full Text] [Related]
2. Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC.
Li W; Guo L; Liu Y; Dong L; Yang L; Chen L; Liu K; Shao Y; Ying J
J Thorac Oncol; 2021 Mar; 16(3):404-418. PubMed ID: 33248323
[TBL] [Abstract] [Full Text] [Related]
3. Different Types of
He Y; Sheng W; Hu W; Lin J; Liu J; Yu B; Mao X; Zhang L; Huang J; Wang G
Oncol Res; 2019 Aug; 27(8):901-910. PubMed ID: 30940295
[No Abstract] [Full Text] [Related]
4. The phosphomimetic mutation of syndecan-4 binds and inhibits Tiam1 modulating Rac1 activity in PDZ interaction-dependent manner.
Keller-Pinter A; Ughy B; Domoki M; Pettko-Szandtner A; Letoha T; Tovari J; Timar J; Szilak L
PLoS One; 2017; 12(11):e0187094. PubMed ID: 29121646
[TBL] [Abstract] [Full Text] [Related]
5. Insights into the molecular roles of heparan sulfate proteoglycans (HSPGs-syndecans) in autocrine and paracrine growth factor signaling in the pathogenesis of Hodgkin's lymphoma.
Gharbaran R
Tumour Biol; 2016 Sep; 37(9):11573-11588. PubMed ID: 27317256
[TBL] [Abstract] [Full Text] [Related]
6. Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.
Le X; Freed JA; VanderLaan PA; Huberman MS; Rangachari D; Jorge SE; Lucena-Araujo AR; Kobayashi SS; Balasubramanian S; He J; Chudnovsky Y; Miller VA; Ali SM; Costa DB
Clin Lung Cancer; 2015 Sep; 16(5):e105-9. PubMed ID: 25922291
[TBL] [Abstract] [Full Text] [Related]
